The Imugene Limited (ASX: IMU) share price is sliding in negative territory today despite a positive company update.
At the time of writing, the immuno-oncology company’s shares are down 7.18% trading at 36 cents. It’s worth noting that Imugene shares have extended its losses to around 25% in the past month.
Imugene secures patent protection
Investors are selling off the Imugene share price amid the broader market slump in the S&P/ASX 200 Index (ASX: XJO) today. The benchmark index is currently down 1.87% to 7,424.1 points, erasing all of this week’s gains.
Nonetheless, Imugene provided the ASX with an upbeat announcement this morning, advising it had secured a patent in South Korea.
Approved by the South Korean Intellectual Property Office, the HER-Vaxx Immunotherapy patent will seek to further protect Imugene’s intellectual property.
HER-Vaxx immunotherapy is B-cell activating immunotherapy designed to treat tumours that over-express the HER-2/neu receptor. Currently in development, the company is designing HER-Vaxx immunotherapy to treat gastric, breast, ovarian, lung and pancreatic cancers.
South Korea has one of the highest incidence rates of gastric cancer across the globe, according to Imugene. Approximately one in five cases are considered to be HER2 positive. This makes the country a very attractive market for gastric cancer medications.
The patent protects the method of composition and method of use of Imugene’s HER-Vaxx immunotherapy for the next 15 years.
Notably, South Korea has been selected to conduct the next HERIZON Phase 2 clinical trial in 2022. The study will use HER-Vaxx in combination with chemotherapy or pembrolizumab in patients who have been diagnosed with gastric cancer.
Imugene managing director and CEO, Leslie Chong commented:
Attaining the key South Korean patent, on top of gaining protection in Japan and China in 2021, is a very important milestone. This will protect HER-Vaxx in the world’s largest HER-2 positive gastric cancer markets until 2036.
Imugene share price snapshot
Despite today’s fall, it has been a solid 12 months for the company’s investors, with the Imugene share price lifting 280%. Its shares reached an all-time high of 62.5 cents in November, before moving on a downhill trend.
Based on today’s price, Imugene has a market capitalisation of roughly $2.19 billion and approximately 5.77 billion shares on issue.
The post Imugene (ASX:IMU) share price backtracks 7% despite milestone update appeared first on The Motley Fool Australia.
Should you invest $1,000 in Imugene right now?
Before you consider Imugene, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
More reading
- These are the 5 best performing ASX shares of 2021
- Why did Pro Medicus (ASX:PME) and 2 other ASX 200 healthcare shares fall today?
- Why is the Imugene (ASX:IMU) share price up 8% today?
- Here are the 5 best performing ASX biotech shares of 2021
- Here are the 3 most heavily traded ASX 200 shares this Tuesday
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3n2sxpX
Leave a Reply